The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MYO | -70.56% | -75.76% | -24.66% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +180% |
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.65M | 28.3% |
| Gross Profit | $6.05M | 13.6% |
| Gross Margin | 62.70% | -8.1% |
| Market Cap | $77.71M | -16.0% |
| Market Cap / Employee | $0.42M | 0.0% |
| Employees | 185 | 74.5% |
| Net Income | -$4.63M | -313.0% |
| EBITDA | -$4.16M | -310.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.24M | 143.6% |
| Accounts Receivable | $7.05M | 179.2% |
| Inventory | 4.1 | 58.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.30M | 19553.2% |
| Short Term Debt | $3.13M | 887.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.99% | 30.1% |
| Return On Invested Capital | -87.30% | 75.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.12M | -397.4% |
| Operating Free Cash Flow | -$8.87M | -362.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.51 | 20.96 | 6.69 | 3.43 | -59.55% |
| Price to Sales | 6.03 | 7.70 | 5.16 | 2.20 | -61.22% |
| Price to Tangible Book Value | 12.51 | 20.96 | 6.69 | 3.43 | -59.55% |
| Enterprise Value to EBITDA | -174.33 | 1059.23 | -60.58 | -20.85 | -81.02% |
| Return on Equity | -82.5% | -36.7% | -35.7% | -68.3% | -33.11% |
| Total Debt | $0.23M | $8.11M | $8.27M | $12.43M | 3315.55% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
